Prognostic Factor Research of Sensory Profiles in Development of Central Sensitization
Launched by VRIJE UNIVERSITEIT BRUSSEL · Jul 21, 2021
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
After performing an univariable linear regression analyses the regression model predicts the dependent variable, central sensitization, significantly, and the models are significant prediction factors of the development of central sensitization. In unadjusted analyses, all four sensory profiles were significantly associated with the development of central sensitization (P\<0.001).
After adjusting for pain, disability, age, and duration of low back pain, baseline sensory profiles remained significant predictors of central sensitization. On the other hand, all other predictor variables did n...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • acute low back pain (\< 6 weeks)
- • with or without radiating pain
- • aged 18 to 60 years
- • a pain-free episode for at least 3 months before the onset of their current back pain
- • read and understand the Dutch language.
- Exclusion Criteria:
- • previous lumbar spinal surgery
- • lumbar radicular syndrome
- • specific cause of low back pain
- • lumbar spinal stenosis
- • current malignancy
- • spondyloarthropathy
- • osteoporosis
- • spondylolisthesis
- • major trauma
- • infection
- • systemic disease.
About Vrije Universiteit Brussel
The Vrije Universiteit Brussel (VUB) is a distinguished research university located in Brussels, Belgium, known for its commitment to innovative education and cutting-edge research across various disciplines. As a clinical trial sponsor, VUB actively engages in advancing medical knowledge and improving patient care through rigorous scientific investigations. The university fosters collaborations with healthcare institutions and industry partners, ensuring that its clinical trials adhere to the highest ethical standards and regulatory requirements. VUB's research initiatives are driven by a multidisciplinary approach, leveraging expertise from fields such as medicine, health sciences, and biomedical engineering to address pressing health challenges and contribute to the development of novel therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussels, , Belgium
Patients applied
Trial Officials
Aldo Scafoglieri, PhD
Study Director
VUB
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials